🇺🇸 FDA
Pipeline program

Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

GCT1046-07

Phase 2 small_molecule active

Quick answer

Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV) is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Genmab A/S
Indication
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials